Michael Megaly to Coronary Restenosis
This is a "connection" page, showing publications Michael Megaly has written about Coronary Restenosis.
Connection Strength
3.802
-
Risk Factors for the Development of Carotid Artery In-Stent Restenosis: Multivariable Analysis. Cardiovasc Revasc Med. 2021 03; 24:65-69.
Score: 0.694
-
Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent Restenosis: A Systematic Review and Meta-Analysis. Cardiovasc Revasc Med. 2021 02; 23:28-35.
Score: 0.693
-
Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis. Cardiovasc Revasc Med. 2021 01; 22:29-33.
Score: 0.684
-
Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis. Catheter Cardiovasc Interv. 2021 01 01; 97(1):32-38.
Score: 0.664
-
Etravirine as a culprit of recurrent drug-eluting in-stent restenosis in an HIV patient. Int J Cardiol. 2016 Sep 15; 219:117-8.
Score: 0.518
-
Outcomes of Intracoronary Brachytherapy for In-Stent Restenosis. Am J Cardiol. 2025 Jun 01; 244:89-98.
Score: 0.238
-
Outcomes with Drug-Coated Balloons in Percutaneous Coronary Intervention in Diabetic Patients. Cardiovasc Revasc Med. 2020 01; 21(1):78-85.
Score: 0.157
-
Outcomes with drug-coated balloons in small-vessel coronary artery disease. Catheter Cardiovasc Interv. 2019 04 01; 93(5):E277-E286.
Score: 0.154